Literature DB >> 28728657

Frequency, Timing, and Impact of Access-Site and Non-Access-Site Bleeding on Mortality Among Patients Undergoing Transcatheter Aortic Valve Replacement.

Raffaele Piccolo1, Thomas Pilgrim1, Anna Franzone1, Marco Valgimigli1, Alan Haynes2, Masahiko Asami1, Jonas Lanz1, Lorenz Räber1, Fabien Praz1, Bettina Langhammer3, Eva Roost3, Stephan Windecker1, Stefan Stortecky4.   

Abstract

OBJECTIVES: The aim of this study was to examine the frequency, timing, and association of access-site and non-access-site bleeding with mortality in the setting of transcatheter aortic valve replacement (TAVR) during long-term follow-up.
BACKGROUND: Bleeding is frequent and associated with impaired prognosis in patients undergoing TAVR. It is currently unknown whether the site of bleeding differentially influences the outcomes of TAVR patients.
METHODS: In total, 926 consecutive patients undergoing TAVR from 2007 through 2014 were evaluated. Bleeding was assessed according to the Valve Academic Research Consortium 2 criteria. The primary outcome of interest was all-cause mortality up to 5 years of follow-up.
RESULTS: A total of 285 patients (30.7%) experienced at least 1 (minor, major, or life-threatening) bleeding event up to 5 years. Compared with patients not experiencing bleeding, the adjusted risk for all-cause mortality was significantly increased among patients with access-site (hazard ratio: 1.34; 95% confidence interval: 1.01 to 1.76; p = 0.04) and non-access-site bleeding (hazard ratio: 2.08; 95% confidence interval: 1.60 to 2.71; p < 0.001). However, non-access-site bleeding conferred a significantly higher risk for mortality compared with access-site bleeding (hazard ratio: 1.56; 95% confidence interval: 1.12 to 2.18; p = 0.009). At multivariate analysis, female sex was a significant correlate of access-site bleeding, whereas chronic kidney disease and the Society of Thoracic Surgeons score were significantly associated with non-access-site bleeding.
CONCLUSIONS: Among patients with severe aortic stenosis undergoing TAVR, access-site and non-access-site bleeding were independently associated with an increased risk for mortality, with the greatest risk related to non-access-site bleeding during long-term follow-up.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  TAVR; access-site bleeding; aortic stenosis; bleeding; non–access-site bleeding

Mesh:

Year:  2017        PMID: 28728657     DOI: 10.1016/j.jcin.2017.04.034

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  20 in total

Review 1.  Transcatheter aortic valve implantation: status update.

Authors:  Antoinette Neylon; Khalid Ahmed; Federico Mercanti; Faisal Sharif; Darren Mylotte
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

Review 2.  Antithrombotic management after transcatheter aortic valve implantation.

Authors:  Fiachra McHugh; Khalid Ahmed; Antoinette Neylon; Faisal Sharif; Darren Mylotte
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

3.  Association of peripheral artery disease with in-hospital outcomes after endovascular transcatheter aortic valve replacement.

Authors:  Divyanshu Mohananey; Pedro Villablanca; Tanush Gupta; Sagar Ranka; Nirmanmoh Bhatia; Oluwole Adegbala; Tomo Ando; Dee Dee Wang; Jose M Wiley; Marvin Eng; Ankur Kalra; Harish Ramakrishna; Binita Shah; William O'Neill; Jorge Saucedo; Deepak L Bhatt
Journal:  Catheter Cardiovasc Interv       Date:  2019-04-25       Impact factor: 2.692

4.  Coronary artery disease and myocardial revascularization in patients undergoing transcatheter aortic valve replacement.

Authors:  Raffaele Piccolo; Anna Franzone; Thomas Pilgrim
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 5.  Access site complications in transcutaneous aortic valve replacement: frequency, outcomes, prevention, and treatment.

Authors:  Samuel Latham; Tamunoinemi Bob-Manuel; Arindam Sharma; Amit Nanda; Devareshi Ardeshna; Rami N Khouzam
Journal:  Ann Transl Med       Date:  2018-01

6.  Use of Medicare Claims to Identify Adverse Clinical Outcomes After Mitral Valve Repair.

Authors:  Angela Lowenstern; Steven J Lippmann; J Matthew Brennan; Tracy Y Wang; Lesley H Curtis; Ted Feldman; Donald D Glower; Bradley G Hammill; Sreekanth Vemulapalli
Journal:  Circ Cardiovasc Interv       Date:  2019-05       Impact factor: 6.546

7.  Outcomes After Transcatheter Mitral Valve Repair in Patients With Renal Disease.

Authors:  Binita Shah; Pedro A Villablanca; Sreekanth Vemulapalli; Pratik Manandhar; Nicholas S Amoroso; Muhamed Saric; Cezar Staniloae; Mathew R Williams
Journal:  Circ Cardiovasc Interv       Date:  2019-02       Impact factor: 6.546

8.  Deep Learning in Prediction of Late Major Bleeding After Transcatheter Aortic Valve Replacement.

Authors:  Yuheng Jia; Gaden Luosang; Yiming Li; Jianyong Wang; Pengyu Li; Tianyuan Xiong; Yijian Li; Yanbiao Liao; Zhengang Zhao; Yong Peng; Yuan Feng; Weili Jiang; Wenjian Li; Xinpei Zhang; Zhang Yi; Mao Chen
Journal:  Clin Epidemiol       Date:  2022-01-12       Impact factor: 4.790

Review 9.  Anticoagulation after Transcatheter Aortic Valve Implantation: Current Status.

Authors:  Antonio Greco; Davide Capodanno
Journal:  Interv Cardiol       Date:  2020-04-23

10.  Predictors and Prognostic Impact of In-hospital Bleeding after Transcatheter Aortic Valve Replacement According to BARC and VARC-2 Definitions.

Authors:  Adrian daSilva-deAbreu; Yelin Zhao; Astrid Serauto-Canache; Bader Alhafez; Katyayini Aribindi; Prakash Balan; Pranav Loyalka; Biswajit Kaaaar; Richard Smalling; H Vernon Anderson; Abhijeet Dhoble; Timo Siepmann; Salman A Arain
Journal:  Braz J Cardiovasc Surg       Date:  2019-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.